Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving β-blockers

Circulation

Volumn 107, Issue 2, 2003, Pages 290-293

  Vittorio, Timothy J ^a   Lang, Chim C ^a   Katz, Stuart D ^a   Packer, Milton ^a   Mancini, Donna M ^a   Jorde, Ulrich P ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Adrenergic receptors; Angiotensin; Congestive heart failure

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PRESSOR RESPONSE; PRIORITY JOURNAL; RADIAL ARTERY; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARBAZOLES; CHRONIC DISEASE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES;

EID: 0037458065     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000045666.04794.14     Document Type: Article

References (35)

1. 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther. 2000;88:281-309.
2. 1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther. 2001;298:403-410.
3. De Jonge A, Knape JTA, Van Meel JCA, et al. Effect of captopril on sympathetic neurotransmission in pithed normotensive rats. Eur J Pharmacol. 1983;88:231-240.
4. Henegar JR, Brower GL, Kabour A, et al. Catecholamine response to chronic angiotensin II infusion and its role in myocyte and coronary, vascular damage. Am J Physiol. 1995;269:H1564-H1569.
5. Marano G, Argiolas L. Postjunctional regulation by angiotensin II of alpha-adrenoceptor-mediated pressor responses in the rat. Eur J Pharmacol. 1994;261:121-126.
6. Seidelin PH, Coutie WR, Pai MS, et al. The interaction between noradrenaline and angiotensin II in man: evidence for a postsynaptic and against a presynaptic interaction. J Hypertens. 1987;5(suppl 5):S121-S124.
7. Lang CC, Rahman AR, Balfour DJK, et al. Prazosin blunts the antinatriuretic effect of angiotensin II in man. J Hypertens. 1992;10:1387-1395.
8. 1-adrenergic receptors in vascular smooth muscle cells. Am J Physiol. 1995;268:H1006-H1014.
9. Luchner A, Stevens TL, Borgeson DD, et al. Angiotensin II in the evolution of experimental heart failure. Hypertension. 1996;28:472-477.
10. Latif F, Tandon S, Obeleniene R, et al. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy normotensive subjects. J Card Fail. 2001;7:265-268.
11. Kendall MJ, Maxwell SRJ, Sandberg A, et al. Controlled release metoprolol: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1991;21:319-330.
12. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 1984;2:581-587.
13. Reid IA. Actions of angiotensin II on the brain: mechanisms and physical role. Am J Physiol. 1984;246:F533-F543.
14. Peach MJ. Adrenal medullary stimulation induced by angiotensin I. angiotensin II and analogues. Circ Res. 1971;28/29:II-107-II-117.
15. Lewis JP, Reit R. Stimulation of the superior cervical ganglion of the cat by angiotensin and bradykinin. J Physiol (Lond). 1965;176:48-55.
16. Boadle MC, Hughes J, Roth RH. Angiotensin accelerates catecholamine biosynthesis in sympathetically mediated tissues. Nature. 1969;222:987-988.
17. Di Bona GF. Neural control of renal function: cardiovascular implications. Hypertension. 1989;13:539-548.
18. 1-adrenoceptor. Am J Physiol. 1997;273:R1224-R1229.
19. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
20. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
21. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular function, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
22. Kubo T, Azevedo E, Newton GE, et al. Lack of evidence for peripheral alpha (1)-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol. 2001;38:1463-1469.
23. Creager MA, Creager SJ. Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. J Am Coll Cardiol. 1994;23:401-405.
24. 1-Blocking properties of carvedilol during acute and chronic administration. J Cardiovasc Pharm. 1992;19(suppl 1):S18-S22.
25. Lohmeier TE, Lohmeier JR, Warren S. Sustained activation of the central baroreceptor pathway in angiotensin hypertension. Hypertension. 2002;39(pt 2):550-556.
26. Mortara A, La Rovere MT, Pinna GD. Non-selective beta-adrenergic blocking agent, carvedilol, improves arterial baroreflex gain and heart rate variability in patients with chronic, stable heart failure. J Am Coll Cardiol. 2000;36:1612-1618.
27. Ohlstein EH, Arleth AJ, Storer B, et al. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 1998;30:167-173.
28. Rossi GP, Sacchetto A, Cesari M, et al. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999;43:300-307.
29. Sanderson JE, Yeung LY, Chan S, et al. Effect of β-blockade on baroreceptor and autonomic function in heart failure. Clin Sci. 1999;96:137-146.
30. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective betaadrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001;104:2194-2199.
31. 2-adrenoceptor and NPY receptor-mediated contractions of porcine isolated blood vessels: evidence for involvement of the vascular endothelium. Br J Pharmacol. 1999;128:1705-1712.
32. Tom B, Schuijt MP, Saxena PR, et al. Angiotensin II-induced vasoconstriction in human coronary arteries: importance of superoxide. Circulation. 2001;104(suppl II):II-181. Abstract.
33. Asbrink S, Zickert A, Bratt J, et al. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharm. 2000;59:1007-1013.
34. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
35. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.